

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | |
|---|--------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| Crimagua Limited | 06/24/2011 |
| RECEIVING PARTY DATA | |
| Name: | Janssen Alzheimer Immunotherapy |
| Street Address: | Little Island Industrial Estate |
| City: | Little Island, County Cork |
| State/Country: | IRELAND |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 11809552 |
| CORRESPONDENCE DATA | |
| Fax Number: | (650)838-2001 |
| <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> | |
| Phone: | 6508382000 |
| Email: | brenda.yamasaki@alston.com |
| Correspondent Name: | Alston & Bird LLP |
| Address Line 1: | 100 South Tryon Street |
| Address Line 2: | Bank of America Plaza, Suite 4000 |
| Address Line 4: | Charlotte, NORTH CAROLINA 28280-4000 |
| ATTORNEY DOCKET NUMBER: | 057437-401957 |
| NAME OF SUBMITTER: | Brenda Yamasaki |
| Total Attachments: 6 source=401957 - 2011 07 21 Executed Assign C to JAI (by both C and JAI)#page1.tif source=401957 - 2011 07 21 Executed Assign C to JAI (by both C and JAI)#page2.tif source=401957 - 2011 07 21 Executed Assign C to JAI (by both C and JAI)#page3.tif source=401957 - 2011 07 21 Executed Assign C to JAI (by both C and JAI)#page4.tif source=401957 - 2011 07 21 Executed Assign C to JAI (by both C and JAI)#page5.tif source=401957 - 2011 07 21 Executed Assign C to JAI (by both C and JAI)#page6.tif | |

CH \$40.00 11809552

ASSIGNMENT

THIS ASSIGNMENT, by CRIMAGUA LIMITED, a private limited company incorporated under the laws of Ireland and having its registered office at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland and successor in interest to Elan Pharma International Limited (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, the Assignor is the owner of the entire right, title and interest of the invention set forth as follows:

Title of Invention: NEUROACTIVE FRAGMENTS OF APP

US Application No.: 11/809,552

Filing Date: June 1, 2007

WHEREAS, JANSSEN ALZHEIMER IMMUNOTHERAPY, a private unlimited company incorporated under the laws of Ireland, and having its registered office at Little Island Industrial Estate, Little Island, County Cork, Republic of Ireland (hereinafter referred to as "the Assignee"), pursuant to an Asset Purchase Agreement dated as of July 2, 2009 (hereinafter referred to as "the Janssen APA"), among Assignor, Assignee, Janssen Pharmaceutical, Janssen Alzheimer Immunotherapy (formerly known as Juno Neurosciences), Elan Corporation, plc, Elan Pharmaceuticals, Inc. and Elan Pharma International Limited, has acquired the Assignor's right, title, and interest in and to said invention and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefor and thereon;



NOW, THEREFORE, pursuant to the Janssen APA, for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over unto the Assignee, and Assignee's successors, legal representatives, and assigns, all of the Assignor's right, title, and interest in and to the above-mentioned invention, the right to file applications on said invention and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all applications claiming priority to said applications, divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had its sale and assignment not been made;


AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, their successors, legal representatives, and assigns, that the Assignor will, whenever counsel of the Assignee, or the counsel of their successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said application, division, continuation, continuation-in-part, substitution or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said inventions, without charge to the Assignor, its successors, legal representatives, and assigns;


AND the Assignor hereby requests the Commissioner of Patents to issue any and all said Letters Patent or Patents of the United States to the Assignee as the Assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

IN TESTIMONY WHEREOF, Assignor has signed its name on the date indicated.

CRIMAGUA LIMITED

Date: June 24, 2011 By: 
 Name: William F. Daniel
Title: Director

Subscribed to by William F. Daniel
with whose identity I have first satisfied myself
this 24th day of June 2011

Andrew F. Smyth, Notary Public
6 Terenure Road East, Rathgar, Dublin 6,
Commissioned for Life



IN TESTIMONY WHEREOF, Assignee has signed its name on the date indicated.

JANSSEN ALZHEIMER IMMUNOTHERAPY

Date: _____

By: _____

Name: Peter L. Herridge

Title: Senior Patent Counsel

EXECUTE IN THE PRESENCE OF A NOTARY

ASSIGNMENT

THIS ASSIGNMENT, by ELAN PHARMA INTERNATIONAL LIMITED, a private limited company incorporated under the laws of Ireland and having its registered office at Monksland, Athlone, County Westmeath, Ireland (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, the Assignor is the owner of the entire right, title and interest of the invention set forth as follows:

Title of Invention: NEUROACTIVE FRAGMENTS OF APP

US Application No.: 11/809,552

Filing Date: June 1, 2007

WHEREAS, CRIMAGUA LIMITED, a private limited company incorporated under the laws of Ireland, and having its registered office at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (hereinafter referred to as "the Assignee"), pursuant to an Asset Purchase Agreement dated as of July 2, 2009 (hereinafter referred to as "the Crimagua APA"), among Assignor, Assignee, Elan Corporation, plc, Elan Pharmaceuticals, Inc., Neuralab Limited and Athena Neurosciences, Inc., has acquired the Assignor's right, title, and interest in and to said invention and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefor and thereon;

NOW, THEREFORE, pursuant to the Crimagua APA, for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over unto the Assignee, and Assignee's successors, legal representatives, and assigns, all of the Assignor's right, title, and interest in and to the above-mentioned invention, the right to file applications on said invention and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all applications claiming priority to said applications, divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had its sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, their successors, legal representatives, and assigns, that the Assignor will, whenever counsel of the Assignee, or the counsel of their successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said application, division, continuation, continuation-in-part, substitution or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said inventions, without charge to the Assignor, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all said Letters Patent or Patents of the United States to the Assignee as the Assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

IN TESTIMONY WHEREOF, Assignor has signed its name on the date indicated.

ELAN PHARMA INTERNATIONAL LIMITED

Date: _____

By: _____

Name: William F. Daniel

Title: Director

IN TESTIMONY WHEREOF, Assignee has signed its name on the date indicated.

JANSSEN ALZHEIMER IMMUNOTHERAPY

Date: July 20, 2011

By: Peter L. Herridge

Name: Peter L. Herridge

Title: Senior Patent Counsel

Sworn to and subscribed
before me this
20 day of July, 2011

Geraldine A. Bailey

GERALDINE A. BAILEY
NOTARY PUBLIC OF NEW JERSEY
Commission Expires 1/14/2014

EXECUTE IN THE PRESENCE OF A NOTARY